DOJ approves $69B CVS-Aetna merger with Part D divestiture

DOJ
Aetna's Part D divestiture satisfied antitrust regulators who approved the $69 billion deal with CVS Wednesday. (skpy/Flickr)

The Department of Justice (DOJ) approved a $69 billion CVS-Aetna merger on Wednesday after Aetna agreed to sell off its Part D business. 

The Part D divestiture was a condition of the merger's approval, according to the DOJ. Late last month, Aetna agreed to sell its 2.2 million Part D business to WellCare. 

RELATED: Aetna sells Part D plans to WellCare in a 'significant step' toward closing CVS deal

Conference

13th Partnering with ACOS & IDNS Summit

This two-day summit taking place on June 10–11, 2019, offers a unique opportunity to have invaluable face-to-face time with key executives from various ACOs and IDNs from the entire nation – totaling over 3.5 million patients served in 2018. Exclusively at this summit, attendees are provided with inside information and data from case studies on how to structure an ACO/IDN pitch, allowing them to gain the tools to position their organization as a “strategic partner” to ACOs and IDNs, rather than a merely a “vendor.”

Suggested Articles

The FTC is suing Surescripts, accusing the health IT company of employing illegal restraints to maintain its monopolies over the e-prescribing market.

Group plans for small businesses may offer a lower-cost option in comparison to individual market coverage, according to a new report. 

Ohio’s attorney general is continuing his war on PBMs, this time by proposing a multi-step plan to improve transparency and lower drug costs.